BCPP Certification Exam Prep 2026 Updated Practice
Questions Comprehensive Psychiatric Pharmacy
Review Detailed Explanations, Verified Answers,
Complete Success Workbook
Question 1
A 45-year-old patient with major depressive disorder (MDD) is initiated on
sertraline. Which of the following is the most common side effect the patient
should be counseled on during the initial weeks of therapy?
A) Weight gain
B) Sedation
C) Nausea
D) Hypertension
Answer: C) Nausea
Rationale: Nausea is one of the most common gastrointestinal side effects of
SSRIs like sertraline, especially during the initial phase of treatment. It is typically
transient and resolves over 1-2 weeks. Weight gain (A) is more common with
long-term SSRI use and some other antidepressants (e.g., mirtazapine, paroxetine).
Sedation (B) is more commonly associated with SSRIs like fluvoxamine or
paroxetine; sertraline is relatively activating. Hypertension (D) is not a typical
SSRI side effect.
Question 2
A patient stabilized on lithium for bipolar disorder presents with new-onset tremor,
confusion, and ataxia. What is the most appropriate initial action?
A) Administer a benzodiazepine for ataxia
B) Obtain a stat serum lithium level
C) Increase the lithium dose to manage emergent symptoms
D) Discontinue lithium immediately
Answer: B) Obtain a stat serum lithium level
,Rationale: The patient's symptoms (tremor, confusion, ataxia) are suggestive of
lithium toxicity. The most appropriate initial action is to obtain a stat serum lithium
level to confirm toxicity and guide further management. Discontinuing lithium
immediately (D) without lab confirmation may be premature. Benzodiazepines (A)
would not address the underlying toxicity, and increasing the dose (C) would
worsen the condition.
Question 3
Which of the following is the preferred first-line pharmacologic treatment for a
patient with severe, non-psychotic major depressive disorder?
A) SSRI (e.g., sertraline)
B) TCA (e.g., amitriptyline)
C) MAOI (e.g., phenelzine)
D) Benzodiazepine (e.g., lorazepam)
Answer: A) SSRI (e.g., sertraline)
Rationale: SSRIs are considered first-line treatment for MDD due to their
favorable side effect profile, ease of dosing, and safety in overdose compared to
TCAs (B) and MAOIs (C). TCAs and MAOIs are typically reserved for treatment-
resistant cases. Benzodiazepines (D) are not antidepressants and are not used as
monotherapy for MDD.
Question 4
A patient with bipolar I disorder is currently experiencing a manic episode. Which
of the following is the most appropriate acute treatment?
A) Sertraline
B) Lithium or an atypical antipsychotic
C) Bupropion
D) Lamotrigine
Answer: B) Lithium or an atypical antipsychotic
Rationale: Acute mania is treated with mood stabilizers (lithium, valproate) or
atypical antipsychotics (olanzapine, risperidone, quetiapine). Antidepressants (A,
,C) can precipitate or worsen mania and should be avoided. Lamotrigine (D) is
effective for maintenance but not for acute mania.
Question 5
A patient with bipolar depression is being initiated on lamotrigine. What is the
most important counseling point regarding this medication?
A) "This medication works immediately for depression"
B) "Report any rash immediately; this medication requires slow dose
titration"
C) "You can take this medication with grapefruit juice"
D) "This medication causes significant weight gain"
Answer: B) "Report any rash immediately; this medication requires slow dose
titration"
Rationale: Lamotrigine carries a black box warning for serious skin rashes,
including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Slow dose titration is essential to minimize this risk. The medication does not work
immediately (A); it requires several weeks for full effect. Grapefruit juice (C) is
not a significant interaction. Weight gain (D) is not a prominent side effect.
Question 6
A patient with MDD has failed trials of two SSRIs. Which of the following is the
most appropriate next step?
A) Add a benzodiazepine
B) Switch to an SNRI (e.g., venlafaxine)
C) Add an antipsychotic
D) Discontinue all medications
Answer: B) Switch to an SNRI (e.g., venlafaxine)
Rationale: For patients who have failed two SSRIs, switching to an SNRI
(venlafaxine, duloxetine) is a reasonable next step. Venlafaxine has evidence of
efficacy in treatment-resistant depression. Adding a benzodiazepine (A) does not
address the underlying depression. Adding an antipsychotic (C) is typically
, reserved for treatment-resistant depression with psychotic features or as
augmentation. Discontinuing all medications (D) is not appropriate.
Question 7
A patient on lithium has a serum level of 1.4 mEq/L. The patient reports mild
tremor and nausea. Which of the following is the most appropriate action?
A) Increase the lithium dose
B) Hold the lithium dose and recheck level
C) Add a beta-blocker for tremor
D) Continue the current dose
Answer: B) Hold the lithium dose and recheck level
Rationale: The therapeutic range for lithium is 0.6-1.2 mEq/L for maintenance. A
level of 1.4 mEq/L with symptoms (tremor, nausea) suggests early toxicity. The
lithium should be held, and the level should be rechecked. Adding a beta-blocker
(C) may help tremor but does not address the elevated level.
Question 8
A patient with bipolar disorder is maintained on lithium and develops
hypothyroidism. Which of the following is the most appropriate management?
A) Discontinue lithium
B) Add levothyroxine
C) Increase lithium dose
D) Add liothyronine
Answer: B) Add levothyroxine
Rationale: Lithium commonly causes hypothyroidism. The appropriate
management is to add levothyroxine while continuing lithium (A) if the patient is
stable on lithium. Liothyronine (D) is T3 and is not typically used for lithium-
induced hypothyroidism.
Questions Comprehensive Psychiatric Pharmacy
Review Detailed Explanations, Verified Answers,
Complete Success Workbook
Question 1
A 45-year-old patient with major depressive disorder (MDD) is initiated on
sertraline. Which of the following is the most common side effect the patient
should be counseled on during the initial weeks of therapy?
A) Weight gain
B) Sedation
C) Nausea
D) Hypertension
Answer: C) Nausea
Rationale: Nausea is one of the most common gastrointestinal side effects of
SSRIs like sertraline, especially during the initial phase of treatment. It is typically
transient and resolves over 1-2 weeks. Weight gain (A) is more common with
long-term SSRI use and some other antidepressants (e.g., mirtazapine, paroxetine).
Sedation (B) is more commonly associated with SSRIs like fluvoxamine or
paroxetine; sertraline is relatively activating. Hypertension (D) is not a typical
SSRI side effect.
Question 2
A patient stabilized on lithium for bipolar disorder presents with new-onset tremor,
confusion, and ataxia. What is the most appropriate initial action?
A) Administer a benzodiazepine for ataxia
B) Obtain a stat serum lithium level
C) Increase the lithium dose to manage emergent symptoms
D) Discontinue lithium immediately
Answer: B) Obtain a stat serum lithium level
,Rationale: The patient's symptoms (tremor, confusion, ataxia) are suggestive of
lithium toxicity. The most appropriate initial action is to obtain a stat serum lithium
level to confirm toxicity and guide further management. Discontinuing lithium
immediately (D) without lab confirmation may be premature. Benzodiazepines (A)
would not address the underlying toxicity, and increasing the dose (C) would
worsen the condition.
Question 3
Which of the following is the preferred first-line pharmacologic treatment for a
patient with severe, non-psychotic major depressive disorder?
A) SSRI (e.g., sertraline)
B) TCA (e.g., amitriptyline)
C) MAOI (e.g., phenelzine)
D) Benzodiazepine (e.g., lorazepam)
Answer: A) SSRI (e.g., sertraline)
Rationale: SSRIs are considered first-line treatment for MDD due to their
favorable side effect profile, ease of dosing, and safety in overdose compared to
TCAs (B) and MAOIs (C). TCAs and MAOIs are typically reserved for treatment-
resistant cases. Benzodiazepines (D) are not antidepressants and are not used as
monotherapy for MDD.
Question 4
A patient with bipolar I disorder is currently experiencing a manic episode. Which
of the following is the most appropriate acute treatment?
A) Sertraline
B) Lithium or an atypical antipsychotic
C) Bupropion
D) Lamotrigine
Answer: B) Lithium or an atypical antipsychotic
Rationale: Acute mania is treated with mood stabilizers (lithium, valproate) or
atypical antipsychotics (olanzapine, risperidone, quetiapine). Antidepressants (A,
,C) can precipitate or worsen mania and should be avoided. Lamotrigine (D) is
effective for maintenance but not for acute mania.
Question 5
A patient with bipolar depression is being initiated on lamotrigine. What is the
most important counseling point regarding this medication?
A) "This medication works immediately for depression"
B) "Report any rash immediately; this medication requires slow dose
titration"
C) "You can take this medication with grapefruit juice"
D) "This medication causes significant weight gain"
Answer: B) "Report any rash immediately; this medication requires slow dose
titration"
Rationale: Lamotrigine carries a black box warning for serious skin rashes,
including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Slow dose titration is essential to minimize this risk. The medication does not work
immediately (A); it requires several weeks for full effect. Grapefruit juice (C) is
not a significant interaction. Weight gain (D) is not a prominent side effect.
Question 6
A patient with MDD has failed trials of two SSRIs. Which of the following is the
most appropriate next step?
A) Add a benzodiazepine
B) Switch to an SNRI (e.g., venlafaxine)
C) Add an antipsychotic
D) Discontinue all medications
Answer: B) Switch to an SNRI (e.g., venlafaxine)
Rationale: For patients who have failed two SSRIs, switching to an SNRI
(venlafaxine, duloxetine) is a reasonable next step. Venlafaxine has evidence of
efficacy in treatment-resistant depression. Adding a benzodiazepine (A) does not
address the underlying depression. Adding an antipsychotic (C) is typically
, reserved for treatment-resistant depression with psychotic features or as
augmentation. Discontinuing all medications (D) is not appropriate.
Question 7
A patient on lithium has a serum level of 1.4 mEq/L. The patient reports mild
tremor and nausea. Which of the following is the most appropriate action?
A) Increase the lithium dose
B) Hold the lithium dose and recheck level
C) Add a beta-blocker for tremor
D) Continue the current dose
Answer: B) Hold the lithium dose and recheck level
Rationale: The therapeutic range for lithium is 0.6-1.2 mEq/L for maintenance. A
level of 1.4 mEq/L with symptoms (tremor, nausea) suggests early toxicity. The
lithium should be held, and the level should be rechecked. Adding a beta-blocker
(C) may help tremor but does not address the elevated level.
Question 8
A patient with bipolar disorder is maintained on lithium and develops
hypothyroidism. Which of the following is the most appropriate management?
A) Discontinue lithium
B) Add levothyroxine
C) Increase lithium dose
D) Add liothyronine
Answer: B) Add levothyroxine
Rationale: Lithium commonly causes hypothyroidism. The appropriate
management is to add levothyroxine while continuing lithium (A) if the patient is
stable on lithium. Liothyronine (D) is T3 and is not typically used for lithium-
induced hypothyroidism.
